托珠单抗在COVID-19相关危重症中的应用:倾向性匹配分析
匹配后托珠单抗组28天ICU死亡率显著更低(23.2% vs 37.8%;风险差-15%;95%CI -29%至-1%),且28天无ICU、无住院、无血管活性药物天数更多,但无机械通气天数及继发感染无差异。作者认为托珠单抗与ICU死亡率降低相关,但需未来RCT验证。
要点
- 匹配后托珠单抗组28天ICU死亡率23.2% vs 未用组37.8%,风险差-15%(95%CI -29%至-1%)。
- 匹配后两组超过85%患者需要机械通气,提示研究对象为重症呼吸衰竭人群。
- 托珠单抗组28天无ICU、无住院、无血管活性药物天数更多,但无机械通气天数无差异。
- 继发感染发生率两组无差异。
- 研究为回顾性观察性队列,倾向性评分匹配基于入ICU来源、CRP、SOFA评分、血管活性药物使用、年龄、种族、体重和机械通气。
适用人群与场景
- 成人COVID-19(SARS-CoV-2感染)患者,入住内科、外科、神经科学或混合ICU,伴有严重低氧性呼吸衰竭。
- 排除人群原文未提及。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:回顾性、观察性、多中心队列研究,2020年3月15日至5月31日,10家Cleveland Clinic Enterprise医院。
- 人群:成人COVID-19患者入住内科、外科、神经科学或混合ICU。
- 干预与对照:托珠单抗 vs 未接受托珠单抗;匹配变量包括入ICU来源、CRP、SOFA评分、血管活性药物使用、年龄、种族、体重和机械通气。
- 主要终点:28天ICU死亡率,托珠单抗组23.2% vs 未用组37.8%,风险差-15%(95%CI -29%至-1%)。
- 关键次要终点:托珠单抗组28天无ICU、无住院、无血管活性药物天数更多;无机械通气天数及继发感染无差异。
- 匹配前托珠单抗组SOFA评分更高(6.1±3.4 vs 4.7±3.6),CRP更高(21.0±10.2 vs 13.7±9.6 mg/dL),插管、血管活性药物需求和肌松剂使用更频繁。
证据类型、等级与局限
- 证据类型:回顾性、观察性、多中心队列研究。
- 证据等级或推荐强度:原文未提及。
- 局限:回顾性设计、样本量有限、倾向性评分匹配可能未完全控制混杂、单中心系统(Cleveland Clinic Enterprise)数据、需前瞻性RCT验证。
对床旁实践的改变
- 该研究提示对COVID-19危重症伴严重低氧性呼吸衰竭患者,托珠单抗可能与28天ICU死亡率降低相关(23.2% vs 37.8%),但为回顾性证据,不能作为常规推荐依据。
- 适用人群为成人COVID-19入住ICU且需机械通气(匹配后超过85%)的重症患者;原文未提及不适用人群。
- 常见陷阱:不能将观察性关联等同于因果,且继发感染无差异但需警惕;原文未提供剂量方案。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: The primary objective was to evaluate ICU mortality at 28 days in patients with severe hypoxemic respiratory failure due to coronavirus disease 2019 infection who received tocilizumab. The secondary objectives were to evaluate ICU-, hospital-, mechanical ventilation-, and vasopressor-free days at day 28 and development of secondary infections.
DESIGN: Retrospective, observational, multicenter, cohort study between March 15, 2020, and May 31, 2020. Using propensity score matching based on ICU admission source, C-reactive protein, Sequential Organ Failure Assessment score, vasopressor use, age, race, weight, and mechanical ventilation, patients who received tocilizumab were matched to patients who did not receive tocilizumab.
SETTING: Ten hospitals within the Cleveland Clinic Enterprise.
PATIENTS: Adult patients admitted to a medical, surgical, neurosciences, or mixed ICU with severe acute respiratory syndrome coronavirus 2 infection.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Four-hundred forty-four patients were included: 342 patients (77%) did not receive tocilizumab and 102 patients (23%) received tocilizumab. Of those, 82 patients in each arm were matched. Before matching, patients who received tocilizumab had higher Sequential Organ Failure Assessment scores (6.1 ± 3.4 vs 4.7 ± 3.6), higher C-reactive protein (21.0 ± 10.2 vs 13.7 ± 9.6 mg/dL), higher frequency of intubation, vasopressor requirement, and paralytics. After matching, characteristics were more balanced and over 85% of patients required mechanical ventilation. ICU mortality was lower in tocilizumab group (23.2% vs 37.8%; risk difference, -15%; 95% CI, -29% to -1%), with more ICU-, hospital-, and vasoactive-free days at day 28 compared with those who did not receive tocilizumab. There was no difference in mechanical ventilation-free days at day 28 or development of secondary infections.
CONCLUSIONS: Tocilizumab use was associated with a significant decrease in ICU mortality in critically ill coronavirus disease 2019 patients with severe hypoxemic respiratory failure. Future randomized controlled trials limited to tocilizumab administration in critically ill coronavirus disease 2019 patients, with severe hypoxemic respiratory failure, are needed to support these findings.
参考来源
- Rajendram P, Sacha GL, Mehkri O, et al. Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis. Crit Care Explor. 2021. PMID: 33490955. doi:10.1097/CCE.0000000000000327
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。